Dyadic International DYAI

Dyadic International Inc is a global biotechnology company based in Jupiter Florida with a satellite office in the Netherlands. The company develops manufactures and commercializes precision engineered animal free recombinant proteins and enzymes for applications in life sciences, food and nutrition, and bio industrial markets. Its core technology consists of two microbial expression platforms known as Dapibus™ and C1 that enable high yield low cost scalable protein production. Over more than two decades Dyadic has refined these platforms to serve research diagnostic food processing and industrial biotechnology customers. The Dapibus™ platform is optimized for non animal proteins used in food nutrition and industrial enzymes while the C1 platform supports high titer secretion of complex biologics such as vaccines and antibodies.

The company generates revenue through direct product sales, distribution partnerships, manufacturing collaborations, and technology licensing agreements. These agreements may include annual licensing fees, milestone payments, development funding, product supply revenues, and revenue sharing arrangements. Dyadic also earns income from profit sharing arrangements with partners such as Fermbox Bio for enzyme products and from royalties on future pharmaceutical commercialization of its C1 platform. In addition, the company receives development funding from government and nonprofit partners that supports platform validation and product pipeline advancement.

The company operates through the following segments. These segments reflect the company’s strategic focus on distinct technology platforms.

• Dapibus™ Protein Production Platform: This segment produces high value non animal proteins and enzymes for non pharmaceutical markets including life sciences, food and nutrition, and bio industrial applications.
• C1 Protein Production Platform: This segment provides a thermophilic fungal expression system for cost effective large scale production of recombinant proteins used in pharmaceutical vaccines antibodies and life science reagents such as albumin, transferrin, fibroblast growth factor, and DNase I.

Dyadic positions itself as a scalable cost effective alternative to traditional expression systems such as CHO cells, E coli, yeast, and insect cells. Its platforms offer high yield expression, simplified downstream purification, and avoidance of viral and endotoxin removal processes. Competitors include large biotechnology firms that rely on mammalian, bacterial, yeast, and insect cell systems as well as emerging precision fermentation companies. Dyadic’s advantages stem from its ability to produce proteins with consistent quality, lower manufacturing costs, and faster development timelines compared with legacy systems. The growing demand for animal free sustainable ingredients further enhances Dyadic’s competitive position in the market.

The company serves life science researchers, diagnostic manufacturers, food and nutrition producers, and bio industrial partners. Notable customers include Proliant Health and Biologicals, Fermbox Bio, Inzymes ApS, The Protein Collective B V, VTT Technical Research Centre of Finland, Rubic One Health, and Phibro Animal Health Abic Biological Laboratories. While the majority of customers are located in North America and Europe, the company also collaborates with partners in Asia and Africa.